IN THE CLAIMS

2. (Amended) The method of claim 36 wherein said tumor [cell is] cells are selected from melanoma, lung, colon, breast, kidney, and prostate.

3. (Unchanged) The method of claim 36 useful for the treatment of cancer selected from the group consisting of melanoma, lung cancer, colon cancer, breast cancer, kidney cancer, and prostate cancer.

5. (Unchanged) The method of claim 36 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-(5-sulfonic 1-naphtyl) ethylene diamine.

6. (Unchanged) The method of claim 36 wherein said hapten is dinitrophenyl.

7. (Unchanged) The method of claim 37 wherein said therapeutically effective amount of cyclophosphamide comprises administering a dose of about 300 mg/M^2 of cyclophosphamide prior to administration of said composition.

10. (Unchanged) The method of claim 36 further comprising sensitizing the patient with a therapeutically effective amount of 1-fluoro-2,4-dinitrobenzene prior to administering cyclophosphamide.

22. (Amended) A composition comprising [a haptenized syngeneic human tumor cell, said haptenized tumor cell substantially in a no growth phase and having the property, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of eliciting T lymphocytes that infiltrate the tumor of said human] human tumor cells that are:

F2

(i) conjugated to a hapten;

(ii) of the same tumor type as a malignant tumor of a patient for treatment of whom the composition is intended;

(iii) autologous to said patient; and

(iv) rendered incapable from growing in the body of a human after they have been injected therein;

said composition eliciting T lymphocytes that infiltrate the patient's tumor when administered to said patient with an adjuvant.

24. (Amended) The composition [method] of claim 22 wherein said tumor [cell is] cells are selected from melanoma, lung, colon, breast, kidney, and prostate.

F3

25. (Amended) The composition of claim 22 wherein said tumor cells are [is] melanoma tumor cells.

26. (Unchanged) The composition of claim 22 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-(5

sylfonic 1-naphtyl) ethylene diamine.

27. (Unchanged) The composition of claim 26 wherein said hapten is dinitrophenyl.

28. (Unchanged) The method of claim 38 wherein said immunological adjuvant is *Bacille Calmette-Guerin*.

34. (Unchanged) A composition of claim 22 further comprising a carrier.

35. (Unchanged) A composition of claim 34 wherein said carrier is selected from the group consisting of saline solution and culture medium.

36. (Amended) A method of treating a malignant tumor in a [human] patient <u>suffering from a malignant tumor by eliciting activated T lymphocytes that infiltrate said tumor, the method</u> comprising administering to said patient:

<u>(a)</u> a composition comprising a therapeutically effective amount of [a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant wherein said human suffers from a malignant tumor of the same type as said tumor cell, and eliciting activated T lymphocytes that infiltrate the tumor of said human] <u>human tumor cells that:</u>

<u>(i) are conjugated to a hapten;</u>

(ii) are of the same tumor type as the patient's tumor;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a human upon injection therein; and

(b) an adjuvant.

37. (Unchanged) The method of claim 36 further comprising administering a therapeutically effective amount of cyclophosphamide prior to administration of said composition.

38. (Unchanged) The composition of claim 22 further comprising an immunological adjuvant.

39. (Amended) A composition comprising [a haptenized syngeneic human tumor cell, said haptenized tumor cell substantially in a no growth phase and having the property, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of] human tumor cells that:

(i) are conjugated to a hapten;

(ii) are of the same tumor type as a malignant tumor of a patient for treatment of whom the composition is intended;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a

human upon injection therein;

said composition eliciting an inflammatory immune response against the tumor of said [human] patient when administered to said patient with an adjuvant.

40. (Amended) A composition comprising [a haptenized syngeneic human tumor cell, said haptenized tumor cell substantially in a no growth phase and having the property, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of] human tumor cells that:

(i) are conjugated to a hapten;

(ii) are of the same tumor type as a malignant tumor of a patient for treatment of whom the composition is intended;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a human upon injection therein;

said composition eliciting a delayed-type hypersensitivity response to the tumor of said [human] patient when administered to said patient with an adjuvant.

41. (Amended) A method of eliciting an inflammatory immune response to a tumor of a [human] patient comprising administering to said [human] patient:

(a) a composition comprising a therapeutically effective amount of [a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant, wherein said human suffers from a malignant tumor of the same type as said tumor

cell, and measuring said inflammatory immune response] human tumor cells that:

(i) are conjugated to a hapten;

(ii) are of the same tumor type as the patient's tumor;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a human upon injection therein; and

(b) an adjuvant.

FS

42. (Amended) A method of eliciting a delayed-type hypersensitivity response to a tumor of a [human] patient comprising administering to said [human] patient

(a) a composition comprising a therapeutically effective amount of [a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant, wherein said human suffers from a malignant tumor of the same type as said tumor cell, and measuring said delayed-type hypersensitivity response] human tumor cells that

(i) are conjugated to a hapten;

(ii) are of the same tumor type as the patient's tumor;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a human upon injection therein; and

(b) an adjuvant.

43. (Amended) A composition comprising [a haptenized syngeneic human tumor cell, said haptenized tumor cell substantially in a no growth phase and having the property, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of] human tumor cells that:

(i) are conjugated to a hapten;

(ii) are of the same tumor type as a malignant tumor of a patient for treatment of whom the composition is intended;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a human upon injection therein;

said composition eliciting an inflammatory immune response against the tumor of said human wherein said tumor is not melanoma.

44. (Amended) A method for treating a malignant tumor in a human patient comprising administering to the patient

(a) a composition comprising a therapeutically effective amount of [a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant wherein said human suffers from a malignant tumor of the same type as said tumor cell, and thereby] human tumor cells that:

(i) are conjugated to a hapten;

(ii) are of the same tumor type as a malignant tumor of a patient for treatment of whom the composition is intended;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a human upon injection therein;

said composition eliciting at least one of the following upon administration to said patient with an adjuvant: an inflammatory immune response against the tumor of said [human] patient; a delayed-type hypersensitivity response against the tumor of said [human] patient and activated T lymphocytes that infiltrate the tumor of said [human] patient wherein said malignant tumor is not melanoma.

45. (Amended) The composition of claim 39 comprising [a plurality of said tumor cells said tumor cells comprising a combination of] intact [and disrupted] tumor cells.

46. (Amended) A method according to claim 36 wherein said composition comprises [a plurality of said tumor cells said tumor cells comprising a combination of] intact [and disrupted] tumor cells.

47. (Amended) A method of treating a malignant tumor in a human patient comprising administering to the patient

a composition comprising a therapeutically effective amount of [a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant wherein said human suffers from a malignant tumor of the same type as said tumor cell, and thereby]

human tumor cells that:

(i) are conjugated to a hapten;

(ii) are of the same tumor type as a malignant tumor of a patient for treatment of whom the composition is intended;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a human upon injection therein;

said composition eliciting at least one of the following upon administration to said patient with an adjuvant: an inflammatory immune response against the tumor of said human; a delayed-type hypersensitivity response against the tumor of said human and activated T lymphocytes that infiltrate the tumor of said human; and

repeating said administration at least six times at spaced apart intervals.

---

48. (Amended) A method of treating a malignant tumor in a human patient comprising administering to the patient

(a) a composition comprising a therapeutically effective amount of [a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant wherein said human suffers from a malignant tumor of the same type as said tumor cell, and thereby] human tumor cells that:

(i) are conjugated to a hapten;

(ii) are of the same tumor type as the patient's tumor;

(iii) are autologous to said patient; and